Abdul Razzaque Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abdul Razzaque Ahmed has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Shawn Shetty
Center for Blistering Diseases and the Department of Dermatology, Tufts University School of Medicine, Boston, MA, USA
7 shared publicationsTegan Nguyen
Center for Blistering Diseases, Department of Dermatology, Tufts University School of Medicine, Boston, MA, USA
6 shared publicationsD. B. Keskin
Department of Cancer Immunology and AIDS, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA
3 shared publicationsKhalaf Kridin
Department of Dermatology, Rambam Health Care Campus, Haifa, Israel
3 shared publicationsMikole Kalesinskas
Department of Dermatology, Center for Blistering Disease, Tufts University School of Medicine, Boston, MA, United States
3 shared publications- Srini Kaveri
Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
3 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1788979
Critical analysis of pemphigus vulgaris in pregnancy
Human pregnancy is a complex, interesting and challenging interplay between the hormonal and immune systems. The presence of an autoimmune disease adds to this complexity. Presence of pemphigus vulgaris (PV) in a pregnant patient should be considered a "high risk pregnancy", by all health care providers involved, from implantation to post-partum care and thereafter. In this systemic review, data from 90 studies involving 111 pemphigus vulgaris patients who were pregnant has been critically analyzed. Patients who had PV before pregnancy and those who developed it during pregnancy were studied and outcomes were compared and are discussed. Systemic corticosteroids (CS) remain the mainstay of treatment. The role of the placenta in producing endogenous cortisol should be considered in adjusting these doses during the last trimester and post-partum. The data in this analysis clearly demonstrates that the clinical and serological control of and the remission of PV is one of the most important factors that influences and predicts maternal health, gestational complications, post-partum exacerbations, neonatal pemphigus and fetal mortality. Observations from this comprehensive review indicate that PV does not preclude successful pregnancy. Critical outcomes measured are probably similar in women who have PV before pregnancy or develop it during pregnancy. The incidence of neonatal pemphigus was 38%, fetal mortality was 9.8% and post-partum flares occurred in 37% of patients. These observations correlated with lack of control of maternal disease during pregnancy. Frequent maternal and fetal monitoring should be considered. Topical therapy should be encouraged since it may decrease the need for higher doses of CS. Azathioprine appears to be the safest immunosuppressive agent in these patients. When available and affordable intravenous immunoglobulin (IVIg) can provide significant benefits. Mucocutaneous disease had more significant consequences than only cutaneous disease. However 70-80% of the patients had oral disease. Therefore oral health care providers should be aware of pemphigus in pregnancy. In some patients, PV may persist after pregnancy, especially if it was present and active post-partum. Patients with PV in a child-bearing age should be advised to get pregnant when PV is in remission. Optimal outcome requires team-work.
- 30 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1788979
Open AccessCritical analysis of pemphigus vulgaris in pregnancy
Human pregnancy is a complex, interesting and challenging interplay between the hormonal and immune systems. The presence of an autoimmune disease adds to this complexity. Presence of pemphigus vulgaris (PV) in a pregnant patient should be considered a "high risk pregnancy", by all health care providers involved, from implantation to post-partum care and thereafter. In this systemic review, data from 90 studies involving 111 pemphigus vulgaris patients who were pregnant has been critically analyzed. Patients who had PV before pregnancy and those who developed it during pregnancy were studied and outcomes were compared and are discussed. Systemic corticosteroids (CS) remain the mainstay of treatment. The role of the placenta in producing endogenous cortisol should be considered in adjusting these doses during the last trimester and post-partum. The data in this analysis clearly demonstrates that the clinical and serological control of and the remission of PV is one of the most important factors that influences and predicts maternal health, gestational complications, post-partum exacerbations, neonatal pemphigus and fetal mortality. Observations from this comprehensive review indicate that PV does not preclude successful pregnancy. Critical outcomes measured are probably similar in women who have PV before pregnancy or develop it during pregnancy. The incidence of neonatal pemphigus was 38%, fetal mortality was 9.8% and post-partum flares occurred in 37% of patients. These observations correlated with lack of control of maternal disease during pregnancy. Frequent maternal and fetal monitoring should be considered. Topical therapy should be encouraged since it may decrease the need for higher doses of CS. Azathioprine appears to be the safest immunosuppressive agent in these patients. When available and affordable intravenous immunoglobulin (IVIg) can provide significant benefits. Mucocutaneous disease had more significant consequences than only cutaneous disease. However 70-80% of the patients had oral disease. Therefore oral health care providers should be aware of pemphigus in pregnancy. In some patients, PV may persist after pregnancy, especially if it was present and active post-partum. Patients with PV in a child-bearing age should be advised to get pregnant when PV is in remission. Optimal outcome requires team-work.
- 28 March 2024
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 151 (2)
Pemphigoid of the pulmonary system
- 28 March 2024
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 151 (2)
Pemphigoid of the pulmonary system
- Open Access
- 12 October 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1267668
Current biologics in treatment of pemphigus foliaceus: a systematic review
Background: Pemphigus foliaceus (PF) differs from pemphigus vulgaris (PV) in that it affects only the skin and mucous membranes are not involved. Pemphigus is commonly treated with systemic corticosteroids and immunosuppressive agents (ISAs). More recently, biologics have been used. The current literature on biologic therapy often combines treatment of PF with PV, hence it is often difficult for clinicians to isolate the treatment of PF from PV. The purpose of this review was to provide information regarding the use of current biological therapy, specifically in PF.Materials and methods: A search of PubMed, Embase, and other databases was conducted using keywords pemphigus foliaceus (PF), rituximab (RTX), intravenous immunoglobulin (IVIg), and biologics. Forty-one studies were included in this review, which produced 105 patients with PF, treated with RTX, IVIg, or a combination of both. Eighty-five patients were treated with RTX, eight patients with IVIg, and 12 received both RTX and IVIg.Results: Most patients in this review had PF that was nonresponsive to conventional immunosuppressive therapies (CIST), and had significant side effects from their use. RTX treatment resulted in complete remission (CR) in 63.2%, a relapse rate of 39.5%, an infection rate of 19.7%, and a mortality rate of 3.9%. Relapse was greater in the lymphoma (LP) protocol than the rheumatoid arthritis (RA) protocol (p<0.0001). IVIg led to CR in 62.5% of patients, with no relapses or infections. Patients receiving both biologics experienced better outcomes when RTX was first administered, then followed by IVIg. Follow-up durations for patients receiving RTX, IVIg, and both were 22.1, 24.8, and 35.7 months, respectively.Discussion: In pemphigus foliaceus patients nonresponsive to conventional immunosuppressive therapy or in those with significant side effects from CIST, RTX and IVIg appear to be useful agents. Profile of clinical response, as well as relapse, infection, and mortality rates in PF patients treated with RTX were similar to those observed in PV patients. The data suggests that protocols specific for PF may produce better outcomes, less adverse effects, and improved quality of life.
- 12 October 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1267668
Open AccessCurrent biologics in treatment of pemphigus foliaceus: a systematic review
Background: Pemphigus foliaceus (PF) differs from pemphigus vulgaris (PV) in that it affects only the skin and mucous membranes are not involved. Pemphigus is commonly treated with systemic corticosteroids and immunosuppressive agents (ISAs). More recently, biologics have been used. The current literature on biologic therapy often combines treatment of PF with PV, hence it is often difficult for clinicians to isolate the treatment of PF from PV. The purpose of this review was to provide information regarding the use of current biological therapy, specifically in PF.Materials and methods: A search of PubMed, Embase, and other databases was conducted using keywords pemphigus foliaceus (PF), rituximab (RTX), intravenous immunoglobulin (IVIg), and biologics. Forty-one studies were included in this review, which produced 105 patients with PF, treated with RTX, IVIg, or a combination of both. Eighty-five patients were treated with RTX, eight patients with IVIg, and 12 received both RTX and IVIg.Results: Most patients in this review had PF that was nonresponsive to conventional immunosuppressive therapies (CIST), and had significant side effects from their use. RTX treatment resulted in complete remission (CR) in 63.2%, a relapse rate of 39.5%, an infection rate of 19.7%, and a mortality rate of 3.9%. Relapse was greater in the lymphoma (LP) protocol than the rheumatoid arthritis (RA) protocol (p<0.0001). IVIg led to CR in 62.5% of patients, with no relapses or infections. Patients receiving both biologics experienced better outcomes when RTX was first administered, then followed by IVIg. Follow-up durations for patients receiving RTX, IVIg, and both were 22.1, 24.8, and 35.7 months, respectively.Discussion: In pemphigus foliaceus patients nonresponsive to conventional immunosuppressive therapy or in those with significant side effects from CIST, RTX and IVIg appear to be useful agents. Profile of clinical response, as well as relapse, infection, and mortality rates in PF patients treated with RTX were similar to those observed in PV patients. The data suggests that protocols specific for PF may produce better outcomes, less adverse effects, and improved quality of life.
- Open Access
- 16 September 2023
- Published by Springer Nature in Cureus
- Vol. 15 (9) , e45373
Treatment of Pediatric Pemphigus Foliaceus
Pemphigus foliaceus (PF) is an autoimmune blistering disease limited to the superficial skin without mucosal involvement. It is clinically, histologically, and immunopathologically distinct from pemphigus vulgaris (PV). As data on pediatric PF is often merged with data on both pediatric and adult PV patients, isolating clinical outcomes in pediatric PF is not always possible. Therefore, the authors of this review analyzed clinical outcomes following therapy in pediatric PF patients only. A search of databases resulted in 33 pediatric patients with PF. In total, 19 (57.6%) patients were treated with conventional immunosuppressive therapies (CISTs), which consisted of systemic corticosteroids and multiple immunosuppressive agents (ISAs). Further, 14 (42.4%) patients were treated with biologic agents, predominantly rituximab (RTX). The mean age of those treated with biologics was 12.8 years (range = 0.88-18 years) compared to 8.9 years (range = 0.92-15 years) of those treated with CIST (p = 0.01). Treatment with biologics was initiated significantly longer after the diagnosis of PF when compared to patients treated with CIST (p = 0.003). RTX was used in all patients who received biologic therapy. Two (6%) patients also received intravenous immunoglobulin. When clinical outcomes were compared between CIST and biologic therapy, rates of clinical remission, partial remission, and relapse, were not statistically significantly different between groups. When RTX was used, rates of relapse and adverse events were higher in those treated with the lymphoma protocol (375 mg/m2 once weekly for four weeks) compared to those treated with the rheumatoid arthritis protocol (two doses of 1,000 mg two weeks apart) (p < 0.0001). The incidence of adverse events was statistically significantly higher in patients treated with CIST when compared to RTX (p = 0.003). These included both physical and psychological changes. The infection rate after treatment with RTX was 7.1%. These outcomes occurred during a follow-up of 12.5 months (range = 1-36 months) in the CIST group and 20.5 months (range = 6-67 months) in the biologic therapy group. The difference in the follow-up period was not statistically significant. The literature suggests that biologics are superior to CIST in treating pemphigus patients. The results of this review suggest similar responses to therapy in pediatric PF patients treated with biologics compared to CIST. This may have been due to a limited duration of follow-up and a lack of detailed treatment outcomes in pediatric PF patients. The data in this review strongly suggests that specific treatment protocols need to be developed and implemented for pediatric PF patients. These patients are at a critical phase in life where PF therapy can influence or affect physical growth, hormonal changes, psychosocial development, and essential education.
- 16 September 2023
- Published by Springer Nature in Cureus
- Vol. 15 (9) , e45373
Open AccessTreatment of Pediatric Pemphigus Foliaceus
Pemphigus foliaceus (PF) is an autoimmune blistering disease limited to the superficial skin without mucosal involvement. It is clinically, histologically, and immunopathologically distinct from pemphigus vulgaris (PV). As data on pediatric PF is often merged with data on both pediatric and adult PV patients, isolating clinical outcomes in pediatric PF is not always possible. Therefore, the authors of this review analyzed clinical outcomes following therapy in pediatric PF patients only. A search of databases resulted in 33 pediatric patients with PF. In total, 19 (57.6%) patients were treated with conventional immunosuppressive therapies (CISTs), which consisted of systemic corticosteroids and multiple immunosuppressive agents (ISAs). Further, 14 (42.4%) patients were treated with biologic agents, predominantly rituximab (RTX). The mean age of those treated with biologics was 12.8 years (range = 0.88-18 years) compared to 8.9 years (range = 0.92-15 years) of those treated with CIST (p = 0.01). Treatment with biologics was initiated significantly longer after the diagnosis of PF when compared to patients treated with CIST (p = 0.003). RTX was used in all patients who received biologic therapy. Two (6%) patients also received intravenous immunoglobulin. When clinical outcomes were compared between CIST and biologic therapy, rates of clinical remission, partial remission, and relapse, were not statistically significantly different between groups. When RTX was used, rates of relapse and adverse events were higher in those treated with the lymphoma protocol (375 mg/m2 once weekly for four weeks) compared to those treated with the rheumatoid arthritis protocol (two doses of 1,000 mg two weeks apart) (p < 0.0001). The incidence of adverse events was statistically significantly higher in patients treated with CIST when compared to RTX (p = 0.003). These included both physical and psychological changes. The infection rate after treatment with RTX was 7.1%. These outcomes occurred during a follow-up of 12.5 months (range = 1-36 months) in the CIST group and 20.5 months (range = 6-67 months) in the biologic therapy group. The difference in the follow-up period was not statistically significant. The literature suggests that biologics are superior to CIST in treating pemphigus patients. The results of this review suggest similar responses to therapy in pediatric PF patients treated with biologics compared to CIST. This may have been due to a limited duration of follow-up and a lack of detailed treatment outcomes in pediatric PF patients. The data in this review strongly suggests that specific treatment protocols need to be developed and implemented for pediatric PF patients. These patients are at a critical phase in life where PF therapy can influence or affect physical growth, hormonal changes, psychosocial development, and essential education.
- Open Access
- 5 September 2023
- Published by Elsevier in Autoimmunity Reviews
- Vol. 22 (10) , 103444
Paraneoplastic autoimmune Laminin-332 syndrome (PALS): Anti-Laminin-332 mucous membrane pemphigoid as a prototype
- 5 September 2023
- Published by Elsevier in Autoimmunity Reviews
- Vol. 22 (10) , 103444
Open AccessParaneoplastic autoimmune Laminin-332 syndrome (PALS): Anti-Laminin-332 mucous membrane pemphigoid as a prototype
- Open Access
- 27 September 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
IgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases Following Various Treatments: Long Term Follow-Up and Relevant Observations
IgM deficiency has been reported in patients with many autoimmune diseases treated with Rituximab (RTX). It has not been studied, in detail, in autoimmune mucocutaneous blistering diseases (AIMBD). Our objectives were: (i) Examine the dynamics of IgM levels in patients with and without RTX. (ii) Influence of reduced serum IgM levels on clinical and laboratory parameters. (iii) Explore the possible molecular and cellular basis for reduced serum IgM levels. This retrospective study that was conducted in a single-center from 2000 to 2020. Serial IgM levels were studied in 348 patients with five AIMBD (pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, and ocular cicatricial pemphigoid) and found decreased in 55 patients treated with RTX, IVIG, and conventional immunosuppressive therapy (CIST). Hence the incidence of decreased serum IgM is low. The incidence of decreased IgM in patients treated with RTX was 19.6%, in patients treated with IVIG and CIST, it was 52.8% amongst the 55 patients. IgM levels in the post-RTX group were statistically significantly different from the IVIG group (p<0.018) and CIST group (p<0.001). There were no statistically significant differences between the groups in other clinical and laboratory measures. Decreased serum IgM did not affect depletion or repopulation of CD19+ B cells. Patients in the three groups achieved clinical and serological remission, in spite of decreased IgM levels. Decrease in IgM was isolated, since IgG and IgA were normal throughout the study period. Decreased IgM persisted at the same level, while the patients were in clinical remission, for several years. In spite of persistent decreased IgM levels, the patients did not develop infections, tumors, other autoimmune diseases, or warrant hospitalization. Studies on IgM deficiency in knockout mice provided valuable insights. There is no universally accepted mechanism that defines decreased IgM levels in AIMBD. The data is complex, multifactorial, sometimes contradictory, and not well understood. Nonetheless, data in this study provides novel information that enhances our understanding of the biology of IgM in health and disease.
- 27 September 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Open AccessIgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases Following Various Treatments: Long Term Follow-Up and Relevant Observations
IgM deficiency has been reported in patients with many autoimmune diseases treated with Rituximab (RTX). It has not been studied, in detail, in autoimmune mucocutaneous blistering diseases (AIMBD). Our objectives were: (i) Examine the dynamics of IgM levels in patients with and without RTX. (ii) Influence of reduced serum IgM levels on clinical and laboratory parameters. (iii) Explore the possible molecular and cellular basis for reduced serum IgM levels. This retrospective study that was conducted in a single-center from 2000 to 2020. Serial IgM levels were studied in 348 patients with five AIMBD (pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, and ocular cicatricial pemphigoid) and found decreased in 55 patients treated with RTX, IVIG, and conventional immunosuppressive therapy (CIST). Hence the incidence of decreased serum IgM is low. The incidence of decreased IgM in patients treated with RTX was 19.6%, in patients treated with IVIG and CIST, it was 52.8% amongst the 55 patients. IgM levels in the post-RTX group were statistically significantly different from the IVIG group (p<0.018) and CIST group (p<0.001). There were no statistically significant differences between the groups in other clinical and laboratory measures. Decreased serum IgM did not affect depletion or repopulation of CD19+ B cells. Patients in the three groups achieved clinical and serological remission, in spite of decreased IgM levels. Decrease in IgM was isolated, since IgG and IgA were normal throughout the study period. Decreased IgM persisted at the same level, while the patients were in clinical remission, for several years. In spite of persistent decreased IgM levels, the patients did not develop infections, tumors, other autoimmune diseases, or warrant hospitalization. Studies on IgM deficiency in knockout mice provided valuable insights. There is no universally accepted mechanism that defines decreased IgM levels in AIMBD. The data is complex, multifactorial, sometimes contradictory, and not well understood. Nonetheless, data in this study provides novel information that enhances our understanding of the biology of IgM in health and disease.
- 3 April 2021
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 21 (4) , 443-454
The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review
Introduction Pemphigus vulgaris (PV) is a life-threatening autoimmune mucocutaneous blistering disease. Systemic corticosteroids (CS), while life-saving, have several serious side effects. To improve treatment and prognosis, recently rituximab (RTX), a chimeric monoclonal antibody against CD20 molecule on B cells, has become popular. This Expert Opinion discusses clinical and scientifically relevant aspects of RTX treating PV. Area Covered This presentation describes the mechanism of action, clinical efficacy, safety, adverse events, protocols used, and clinical outcomes. Concerns for infection, reactivation of latent or previous infections, and high relapse rate are discussed. Expert opinion Use of RTX in PV is still a work in progress. There are many unanswered questions. FDA did not provide a protocol or guidelines. Whenever RTX is used, systemic corticosteroids are simultaneously used, albeit for a shorter duration and lower dose. Used in these doses for these durations they can cause immunosuppression. Would it be more appropriate if instead of 'First Line Therapy' it would be more advisable to use the term 'First Adjunctive Immunosuppressive Agent'?
- 3 April 2021
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 21 (4) , 443-454
The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review
Introduction Pemphigus vulgaris (PV) is a life-threatening autoimmune mucocutaneous blistering disease. Systemic corticosteroids (CS), while life-saving, have several serious side effects. To improve treatment and prognosis, recently rituximab (RTX), a chimeric monoclonal antibody against CD20 molecule on B cells, has become popular. This Expert Opinion discusses clinical and scientifically relevant aspects of RTX treating PV. Area Covered This presentation describes the mechanism of action, clinical efficacy, safety, adverse events, protocols used, and clinical outcomes. Concerns for infection, reactivation of latent or previous infections, and high relapse rate are discussed. Expert opinion Use of RTX in PV is still a work in progress. There are many unanswered questions. FDA did not provide a protocol or guidelines. Whenever RTX is used, systemic corticosteroids are simultaneously used, albeit for a shorter duration and lower dose. Used in these doses for these durations they can cause immunosuppression. Would it be more appropriate if instead of 'First Line Therapy' it would be more advisable to use the term 'First Adjunctive Immunosuppressive Agent'?
- 1 March 2020
- Published by Elsevier in Autoimmunity Reviews
- Vol. 19 (3) , 102466
Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia
- 1 March 2020
- Published by Elsevier in Autoimmunity Reviews
- Vol. 19 (3) , 102466
Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia
- Open Access
- 22 October 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 2466
Anti-p200 Pemphigoid: A Systematic Review
The many clinical aspects of anti-p200 pemphigoid are not well-characterized. We aimed to analyze and correlate known existing data on the epidemiological, clinical, histological, and immunological features of anti-p200 pemphigoid. We performed a review using Medline, Embase, and Web of Science databases (1900–2018). Case reports and series of patients were included. A total of 68 eligible studies that comprised 113 anti-p200 pemphigoid patients were included in the qualitative analysis, where there was a mean age of onset of 65.5 years. All patients presented with bullae/vesicles, and 54.3% had urticarial plaques. A similarity to bullous pemphigoid was reported in 66.1% of cases, but palmoplantar (51.4%), cephalic (40.3%), and mucosal (38.5%) involvement, besides frequent development of scars/milia (15.7%), were reported. Autoantibodies against recombinant laminin γ1 were detected in the sera of 73.1% of patients. Psoriasis was present in 28.3% of anti-p200 pemphigoid patients, particularly among Japanese patients (56.4%). The incidence of pustular psoriasis in this subgroup, was significantly greater than in the normal population. In conclusion, the diagnosis of anti-p200 pemphigoid may be suspected when a subepidermal autoimmune blistering disease develops in a younger age group, along with significant acral and cephalic distribution and mucosal involvement.
- 22 October 2019
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 2466
Open AccessAnti-p200 Pemphigoid: A Systematic Review
The many clinical aspects of anti-p200 pemphigoid are not well-characterized. We aimed to analyze and correlate known existing data on the epidemiological, clinical, histological, and immunological features of anti-p200 pemphigoid. We performed a review using Medline, Embase, and Web of Science databases (1900–2018). Case reports and series of patients were included. A total of 68 eligible studies that comprised 113 anti-p200 pemphigoid patients were included in the qualitative analysis, where there was a mean age of onset of 65.5 years. All patients presented with bullae/vesicles, and 54.3% had urticarial plaques. A similarity to bullous pemphigoid was reported in 66.1% of cases, but palmoplantar (51.4%), cephalic (40.3%), and mucosal (38.5%) involvement, besides frequent development of scars/milia (15.7%), were reported. Autoantibodies against recombinant laminin γ1 were detected in the sera of 73.1% of patients. Psoriasis was present in 28.3% of anti-p200 pemphigoid patients, particularly among Japanese patients (56.4%). The incidence of pustular psoriasis in this subgroup, was significantly greater than in the normal population. In conclusion, the diagnosis of anti-p200 pemphigoid may be suspected when a subepidermal autoimmune blistering disease develops in a younger age group, along with significant acral and cephalic distribution and mucosal involvement.
- 3 October 2019
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 15 (10) , 1061-1071
Treatment of pemphigus vulgaris: part 2 – emerging therapies
Introduction: Corticosteroids and immunosuppressive agents have been the mainstay for the treatment of pemphigus vulgaris (PV) for several decades. While these agents have benefited numerous patients, they have been associated with the risks of prolonged immune suppression and have a high incidence of significant and catastrophic side effects. These side effects can be dose limiting. Relapses are frequent. Novel agents promising targeted therapies, that may be provide better outcomes, are being studied. Areas covered: Recently anti-CD20 therapy in combination with corticosteroids has been recommended as the first line treatment for PV. A number of known and new therapeutic agents currently being studied are, BAFF, P13K, BTK inhibitors along with the use of IVIg and CAR-T therapy. Understanding the proposed therapeutic targets and their possible role in pathophysiology appears to be the rationale for these therapies. If successful they may be valuable to clinicians treating PV by providing them with more therapeutic options, for the treatment of this potentially fatal disease. Expert opinion: Investigators studying these emerging therapies have used agents which have shown some positive outcomes in other autoimmune diseases. Their hope and vision are that they may produce favorable outcomes in PV. While there is significant enthusiasm for these therapies, certain concerns and consequences are being underdiscussed. None of the current clinical trials in progress are specific for PV, except possibly CAR-T therapy, if it can be safely done in human patients. The major issue(s) that are unclear is whether these therapies would be successful in providing long term clinical remissions. Is it possible that they may be needed for long term maintenance of remission? Will these therapies require additional agents to be effective and whether these benefits would be of limited duration? The answers to these and many more questions will determine their final place in the algorithm for the treatment of PV.
- 3 October 2019
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 15 (10) , 1061-1071
Treatment of pemphigus vulgaris: part 2 – emerging therapies
Introduction: Corticosteroids and immunosuppressive agents have been the mainstay for the treatment of pemphigus vulgaris (PV) for several decades. While these agents have benefited numerous patients, they have been associated with the risks of prolonged immune suppression and have a high incidence of significant and catastrophic side effects. These side effects can be dose limiting. Relapses are frequent. Novel agents promising targeted therapies, that may be provide better outcomes, are being studied. Areas covered: Recently anti-CD20 therapy in combination with corticosteroids has been recommended as the first line treatment for PV. A number of known and new therapeutic agents currently being studied are, BAFF, P13K, BTK inhibitors along with the use of IVIg and CAR-T therapy. Understanding the proposed therapeutic targets and their possible role in pathophysiology appears to be the rationale for these therapies. If successful they may be valuable to clinicians treating PV by providing them with more therapeutic options, for the treatment of this potentially fatal disease. Expert opinion: Investigators studying these emerging therapies have used agents which have shown some positive outcomes in other autoimmune diseases. Their hope and vision are that they may produce favorable outcomes in PV. While there is significant enthusiasm for these therapies, certain concerns and consequences are being underdiscussed. None of the current clinical trials in progress are specific for PV, except possibly CAR-T therapy, if it can be safely done in human patients. The major issue(s) that are unclear is whether these therapies would be successful in providing long term clinical remissions. Is it possible that they may be needed for long term maintenance of remission? Will these therapies require additional agents to be effective and whether these benefits would be of limited duration? The answers to these and many more questions will determine their final place in the algorithm for the treatment of PV.